Ecarnot Fiona, Quenot Jean-Pierre, Besch Guillaume, Piton Gaël
Department of Cardiology, University Hospital, Besancon, France.
EA3920, University of Burgundy Franche-Comté, Besancon, France.
Ann Transl Med. 2017 Dec;5(Suppl 4):S41. doi: 10.21037/atm.2017.04.42.
Clinical research remains a vital contributor to medical knowledge, and is an established and integral part of the practice of medicine worldwide. Respect for patient autonomy and ethical principles dictate that informed consent must be obtained from subjects before they can be enrolled into clinical research, yet these conditions may be difficult to apply in real practice in the intensive care unit (ICU). A number of factors serve to complexify the consent process in critically ill patients, notably decisional incapacity of the patient due to illness or sedation. Obtaining consent for research from a designated proxy or family member, commonly termed a "surrogate decision maker" (SDM) may be difficult, since SDMs dealing with the emotional, psychological and logistic impact of a sudden hospitalisation of their loved-one are not always receptive to the idea of research or emotionally equipped to reflect rationally on the opportunities being proposed to them. In addition, time constraints and workload pressures on the attending physician may render consent opportunities unfeasible, and the resulting loss of eligible patients could represent a bias in clinical trials, or limit the generalizability of their results. Alternative procedures such as deferred or waived consent have been used in the past and may be suitable alternatives in certain conditions, provided appropriate approval from institutional review boards (IRBs) can be obtained, in accordance with existing legislation. Some of the main questions inherent to the conduct of clinical research in critically ill patients are discussed in this review.
临床研究仍然是医学知识的重要贡献者,并且是全球医学实践中既定且不可或缺的一部分。尊重患者自主权和伦理原则规定,在将受试者纳入临床研究之前,必须获得他们的知情同意,但在重症监护病房(ICU)的实际操作中,这些条件可能难以适用。许多因素使得重症患者的同意过程变得复杂,尤其是患者因疾病或镇静而无决策能力。从指定的代理人或家庭成员(通常称为“替代决策者”[SDM])那里获得研究同意可能很困难,因为处理亲人突然住院所带来的情感、心理和后勤影响的SDM并不总是接受研究的想法,或者在情感上没有能力理性地思考向他们提出的机会。此外,主治医生面临的时间限制和工作量压力可能使同意的机会变得不可行,而导致符合条件的患者流失可能会在临床试验中造成偏差,或者限制试验结果的普遍性。过去曾使用过诸如延迟或豁免同意等替代程序,并且在某些条件下可能是合适的替代方法,但前提是要根据现行法律获得机构审查委员会(IRB)的适当批准。本综述讨论了重症患者临床研究中固有的一些主要问题。